The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia

  title={The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia},
  author={Peter Malik and Maibritt B. Andersen and Linda Peacock},
  journal={Pharmacology Biochemistry and Behavior},
Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model
It is suggested for the first time that upregulated striatal D3 receptors correlate with TD in nonhuman primates, adding new insights to the dopamine receptor supersensitivity hypothesis.
The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment
The study clearly shows that the African-Carribean population differs from the Caucasian population with regard to the association of TD with the polymorphisms studied and suggests that the association is the result of a changed susceptibility of the patients, independent of the action of the antipsychotics on these receptors.
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Pramipexole may be a therapeutic option for treating LID because its effects on D3 dopamine receptors may balance the D1 dopamine receptor supersensitivity associated with LID.
A late appearance by the dopamine D‐3 receptor
  • P. Jenner
  • Psychology, Biology
    Movement disorders : official journal of the Movement Disorder Society
  • 2014
The D-3 dopamine receptor was first cloned in 1990 and was shown to be present largely in limbic regions of the brain, with much lower levels expressed in striatal areas, which suggests that despite opposing actions on postsynaptic striatal dopamine receptors, dopamine agonist and antagonist compounds might induce common changes linked to dyskinesia induction.
Pramipexole reduces parkinsonian tremor induced by pilocarpine infusion in the rat striatum
Identification and Characterization of a Novel Class of Atypical Dopamine Receptor Agonists
A novel class of atypical dopamine receptor agonists that include three structurally dissimilar compounds that will help determine the physiological and pathophysiological relevance of D3 receptor tolerance and SRT properties are discovered.
Animal models of tardive dyskinesia.
Medication-Induced Tardive Dyskinesia: A Review and Update.
The reported incidence of TD seems to be reduced with the use of atypical antipsychotic drugs, yet the risk of developing TD remains with these medications, and the need for a prevention-based focus of TD treatment is highlighted.


Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity
It is indicated that D-1 antagonists such as NNC 756 elicit fewer extrapyramidal symptoms (both acute and tardive) than D-2 antagonistssuch as raclopride, although extremely high doses may cause a special grooming withdrawal syndrome.
Dopamine Receptor Agonist- and Antagonist‐Induced Behaviors in Primates Previously Treated with Dopamine Receptor Antagonists: The Pathogenetic Mechanisms of Acute Oral Dyskinesia
  • H. Lublin
  • Biology, Psychology
    Clinical neuropharmacology
  • 1995
It is suggested that oral dyskinesia and grooming are independent but most often simultaneously occurring behaviors, and varying interactions between dopaminergic receptor subtypes in different types of dopaminaergic behaviors are suggested.
New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects
The TIs of the new and potential antipsychotics were 3–5 versus 4 for clozapine and 1 for haloperidol and melperone, suggesting that like clozamine, these new drugs will not produce EPS at antipsychotic doses.
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
Investigation of the genetic variation of the dopamine D3 receptor gene (DRD3) as a putative risk factor for TD in schizophrenic patients receiving long-term anti-psychotic drug therapy indicates that autosomal inheritance of two polymorphic Ser9Gly alleles, but not homozygosity for the wild-type allele (1-1 genotype), is a susceptibility factor for the development of TD.
The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys
Though the differential effect on amphetamine- and apomorphine-induced behaviours is intriguing, CGS 21680 showed a functional anti-dopaminergic effect in Cebus apella monkeys without production of EPS, substantiates that adenosine A2A receptor agonists may have potential as antipsychotics with atypical profiles.
Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907.